Drug Trial Radar · NCT03493854
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Actual
Start
Jun 14, 2018
Primary completion
Jul 4, 2019
Study completion Jun 2, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.
Conditions
- Early Breast Cancer
Interventions
CyclophosphamideDrug
Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
DoxorubicinDrug
Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
DocetaxelDrug
As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
PaclitaxelDrug
As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
Pertuzumab IVDrug
Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
FDC of Pertuzumab and Trastuzumab SCDrug
The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
Trastuzumab IVDrug
Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
Trastuzumab SCDrug
After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
SurgeryProcedure
Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
Post-operative RadiotherapyRadiation
If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
Hormone TherapyDrug
For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)Time frame: Pre-dose on Cycle 8, Day 1 (up to 21 weeks)
Locations
107 sites in 19 countries. Site status is shown where the registry gives one.
Maryland Oncology Hematology
Rockville, Maryland
San Juan Oncology Associates
Farmington, New Mexico
Levine Cancer Institute
Charlotte, North Carolina
Northwest Medical Specialties
Lakewood, Washington
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
COIBA
Provincia de Buenos Aires, Argentina
Institut Jules Bordet
Anderlecht, Belgium
GHdC Site Notre Dame
Charleroi, Belgium
UZ Antwerpen
Edegem, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Clinique Ste-Elisabeth
Namur, Belgium
Hospital Araujo Jorge; Departamento de Ginecologia E Mama
Goiânia, Goiás, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Perola Byington
São Paulo, São Paulo, Brazil
Royal Victoria Hospital
Barrie, Ontario, Canada
Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center
Oshawa, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont
Sherbrooke, Quebec, Canada
Masarykuv onkologicky ustav
Brno, Czechia
Multiscan s.r.o.
Pardubice, Czechia
ICO Paul Papin; Oncologie Medicale.
Angers, France
Institut Sainte Catherine
Avignon, France
CHRU Besançon
Besançon, France
Institut Bergonie; Oncologie
Bordeaux, France
Centre Léon Bérard
Lyon, France
Institut Curie; Oncologie Medicale
Paris, France
APHP - Hospital Saint Louis
Paris, France
ICO - Site René Gauducheau
Saint-Herblain, France
Klinikum Augsburg; Frauenklinik
Augsburg, Germany
Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie
Bad Nauheim, Germany
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, Germany
St. Johannes-Hospital
Dortmund, Germany
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum
Essen, Germany
Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem
Hamburg, Germany
Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe
Offenbach, Germany
Gynäkologie Kompetenzzentrum; Praxis Dr. med. Carsten Hielscher
Stralsund, Germany
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica
Naples, Campania, Italy
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.